Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population

Suwalska, Katarzyna; Pawlak, Edyta; Karabon, Lidia; Tomkiewicz, Anna; Dobosz, Tadeusz; Urbaniak-Kujda, Donata; Kuliczkowski, Kazimierz; Wołowiec, Dariusz; Jedynak, Anna; Frydecka, Irena

doi:10.1016/j.humimm.2008.01.014

Cited by 52 publications

(66 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the described ICOS SNPs leads to changes in amino acid, while a few have been demonstrated to be functional variants [17][18][19][20]. The chromosomal region of 2q33 harboring the CD28, CTLA-4, and ICOS gene family has been described as carrying predisposing genes for several autoimmune diseases [19,[21][22][23] and, recently, for cancer [24][25][26]. Our recent results indicate that the ICOS microsatellite polymorphism c.1554+4GT(8_15) is associated with susceptibility to B-CLL [24].…”

Section: Introductionmentioning

confidence: 77%

<i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population

Karabon¹,

Jedynak²,

Tomkiewicz³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:There is strong evidence that altered immunological function entails an increased risk of B-cell chronic lymphocytic leukemia (B-CLL). The main mechanism of an anti-tumor response depends on T-cell activation. Unlike the constitutively expressed CD28, inducible costimulatory molecule (ICOS) is expressed on the T-cell surface after activation. ICOS enhances all the basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, the upregulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B cells. ICOS is essential for both efficient interaction between T and B cells and normal antibody responses to T cell-dependent antigens. It does not upregulate the production of interleukin-2, but superinduces the synthesis of interleukin-10. Our previous results indicated the ICOS gene has a role as a susceptibility locus to B-CLL. Therefore an extended study was undertaken to evaluate the association between four ICOS polymorphisms (which were recently described as functional ones) and susceptibility to B-CLL in the Polish population. A case-control study of 296 individuals, including 146 B-CLL patients, was conducted on four polymorphisms in the ICOS gene. Genotyping of the polymorphisms ICOS ISV1+173T>C (rs10932029), ICOSc.1624C>T (rs10932037), ICOSc.2373G>C (rs4675379), and ICOSc.602A>C (rs10183087) was carried out using allelic discrimination methods with the TaqMan ® SNP Genotyping Assay. There were no statistically significant differences in the allele, genotype, or haplotype distributions between B-CLL patients and healthy controls for any of the investigated polymorphic markers in the ICOS gene.

show abstract

Section: Introductionmentioning

confidence: 77%

<i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population

Karabon¹,

Jedynak²,

Tomkiewicz³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…Therefore the [T] allele may contribute to the upregulation of the expression of the down-regulatory CTLA-4 molecule, inhibition of the activation of T lymphocytes, and eventually limitation of the potency of antitumor immunity, and in that way susceptibility to cancer. Previously we have shown an association between this promoter polymorphism and B-cell chronic lymphocytic leukemia [30]. Moreover, it was found by us and others that the same allele confers susceptibility to female-related cancers: sporadic breast cancer [31,48], and cervical cancer [29,32] as well as non-small cell lung cancer in women [24].…”

Section: Discussionmentioning

confidence: 80%

“…Interestingly, the opposite results for this SNP were shown for mucosa-associated lymphoid tissue lymphoma [43] and multiple myeloma [44], while no associations with cancer risk were observed for colorectal cancer [45], chronic lymphocytic leukemia [30], cervical squamous cell carcinoma [29], malignant melanoma [46], or non-malignant melanoma [47].…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?

Karabon

Tupikowski

Tomkiewicz

et al. 2017

Pathol. Oncol. Res.

Self Cite

View full text Add to dashboard Cite

The impairment of immunological surveillance caused by aberrant T cell activation can lead to an inadequate anti-tumor response. Therefore, deregulation in co-stimulatory pathway might be associated with cancer susceptibility. Here we undertook a prospective study to investigate whether genetic variations in gene encoding molecule CD28 and CTLA-4 playing pivotal role in regulating adoptive immune response can influence susceptibility to prostate cancer. Single nucleotide polymorphisms (SNPs) in CTLA-4 and CD28 genes were genotyped in 301 prostate cancer (PCa) patients and 301 controls. The distributions of the genotypes and haplotypes in the CTLA-4/CD28 SNPs were similar in both studied groups. However, the overrepresentation of carriers of CTLA4c.49A>G[A] allele and carriers of CTLA-4g.319C>T[T] allele in PCa as compared to controls was observed (p = 0.082 and p = 0.13, respectively). The risk of disease was higher (OR 1.78) for carriers of both susceptibility alleles as compared to carriers of protective genotypes (p = 0.03). The CTLA4c.49A>G and CTLA-4g.319C>T SNPs might be considered as low risk susceptibility locus for PCa.

show abstract

“…CTLA-4 has also been implicated to serve functions in neoplastic cells, including B cell chronic lymphocytic leukaemia (10), non-Hodgkin's lymphoma (11), breast cancer (12), lung cancer (13), melanoma (14), gastric cancer (15), colorectal cancer (15), cervical cancer (16) and oesophageal carcinoma (17). Prior studies indicated that CTLA-4 expression in tumour cells is associated with poor prognosis (12,17).…”

Section: Introductionmentioning

confidence: 99%

Potential function of CTLA‑4 in the tumourigenic capacity of melanoma stem cells

Zhang

Dang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Extensive clinical evidence supports that cytotoxic T lymphocyte antigen-4 (CTLA-4) is expressed in a variety of human malignant tumour cells in addition to T cells. In certain types of cancer, the overexpression of CTLA-4 is associated with poor patient prognosis. However, few studies have demonstrated the effects of tumour-intrinsic CTLA-4 in cancer stem cells, including melanoma stem cells (MSCs). In the present study, it was demonstrated that melanoma cell-intrinsic CTLA-4 induced tumour cell proliferation in vitro and suppressed tumour cell apoptosis. Furthermore, CTLA-4 was expressed in aldehyde dehydrogenase (ALDH) + MSCs. CTLA-4 inhibited MSCs proliferation in vitro by blocking antibodies and significantly downregulated ALDH1A1, ALDH1A3 and ALDH2 mRNA expression (P<0.01). Functionally, blocking CTLA-4 in melanoma cell lines suppressed the properties of stem-like cells, including ALDH activity and significantly suppressed the ability of these cells to form spheres in vitro (P<0.05). In addition, the blocking of CTLA-4 in melanoma cells suppressed the properties of stem-like cells in vivo, including the capacity for tumourigenesis. The presence of residual ALDH + MSCs within the tumour was observed, and the blocking CTLA-4 significantly decreased the number of residual ALDH + MSCs in vivo (P<0.01). Altogether, these results indicate the identification of a novel mechanism underlying melanoma progression in the present study and that CTLA-4-targeted therapy may benefit candidate CTLA-4-targeted therapy by improving the long-term outcome for patients with advanced stages of melanoma.

show abstract

Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population

Cited by 52 publications

References 43 publications

<i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population

<i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population

Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?

Potential function of CTLA‑4 in the tumourigenic capacity of melanoma stem cells

Contact Info

Product

Resources

About